277 related articles for article (PubMed ID: 22336153)
1. [Clinicopathologic and immunohistochemical study of 187 cases of intraductal papillary neoplasm of breast].
Zhang H; Xiong Y; Zhang S; Zhang Y; Wang YH; Li T
Zhonghua Bing Li Xue Za Zhi; 2011 Nov; 40(11):726-31. PubMed ID: 22336153
[TBL] [Abstract][Full Text] [Related]
2. The role of immunohistochemistry for smooth-muscle actin, p63, CD10 and cytokeratin 14 in the differential diagnosis of papillary lesions of the breast.
Tse GM; Tan PH; Lui PC; Gilks CB; Poon CS; Ma TK; Law BK; Lam WW
J Clin Pathol; 2007 Mar; 60(3):315-20. PubMed ID: 16698948
[TBL] [Abstract][Full Text] [Related]
3. [Papillary lesions of the breast].
Ni YB; Tse GM
Zhonghua Bing Li Xue Za Zhi; 2013 Nov; 42(11):721-6. PubMed ID: 24447546
[No Abstract] [Full Text] [Related]
4. Double immunostaining with p63 and high-molecular-weight cytokeratins distinguishes borderline papillary lesions of the breast.
Ichihara S; Fujimoto T; Hashimoto K; Moritani S; Hasegawa M; Yokoi T
Pathol Int; 2007 Mar; 57(3):126-32. PubMed ID: 17295644
[TBL] [Abstract][Full Text] [Related]
5. Myoepithelial cells in solid variant of intraductal papillary carcinoma of the breast: a potential diagnostic pitfall and a proposal of an immunohistochemical panel in the differential diagnosis with intraductal papilloma with usual ductal hyperplasia.
Moritani S; Ichihara S; Kushima R; Okabe H; Bamba M; Kobayashi TK; Hattori T
Virchows Arch; 2007 May; 450(5):539-47. PubMed ID: 17377808
[TBL] [Abstract][Full Text] [Related]
6. Cytokeratins in papillary lesions of the breast: is there a role in distinguishing intraductal papilloma from papillary ductal carcinoma in situ?
Tan PH; Aw MY; Yip G; Bay BH; Sii LH; Murugaya S; Tse GM
Am J Surg Pathol; 2005 May; 29(5):625-32. PubMed ID: 15832086
[TBL] [Abstract][Full Text] [Related]
7. Combined evaluation of CK5/6, ER, p63, and MUC3 for distinguishing breast intraductal papilloma from ductal carcinoma in situ.
Furuya C; Kawano H; Yamanouchi T; Oga A; Ueda J; Takahashi M
Pathol Int; 2012 Jun; 62(6):381-90. PubMed ID: 22612506
[TBL] [Abstract][Full Text] [Related]
8. Papillary Lesions of the Breast: A Practical Approach to Diagnosis.
Jorns JM
Arch Pathol Lab Med; 2016 Oct; 140(10):1052-9. PubMed ID: 27684976
[TBL] [Abstract][Full Text] [Related]
9. A useful immunohistochemical approach to evaluate intraductal proliferative lesions of the breast and to predict their prognosis.
Omi Y; Yamamoto T; Okamoto T; Obara T; Kobayashi M
Histol Histopathol; 2011 Jan; 26(1):79-86. PubMed ID: 21117029
[TBL] [Abstract][Full Text] [Related]
10. Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.
Nassar A; Sussman ZM; Lawson D; Cohen C
Breast J; 2012 Sep; 18(5):399-405. PubMed ID: 22882580
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical staining of papillary breast lesions.
Troxell ML; Masek M; Sibley RK
Appl Immunohistochem Mol Morphol; 2007 Jun; 15(2):145-53. PubMed ID: 17525625
[TBL] [Abstract][Full Text] [Related]
12. Cytokeratin 5 and estrogen receptor immunohistochemistry as a useful adjunct in identifying atypical papillary lesions on breast needle core biopsy.
Grin A; O'Malley FP; Mulligan AM
Am J Surg Pathol; 2009 Nov; 33(11):1615-23. PubMed ID: 19675450
[TBL] [Abstract][Full Text] [Related]
13. [Value of CK5/6, CK14, ER and PR detection in differential diagnosis of intraductal proliferative lesions of the breast].
Niu F; Wang L; Zhang W; Lyu S; Niu Y
Zhonghua Zhong Liu Za Zhi; 2015 Oct; 37(10):749-52. PubMed ID: 26813593
[TBL] [Abstract][Full Text] [Related]
14. Myoepithelial cell staining patterns of papillary breast lesions: from intraductal papillomas to invasive papillary carcinomas.
Hill CB; Yeh IT
Am J Clin Pathol; 2005 Jan; 123(1):36-44. PubMed ID: 15762278
[TBL] [Abstract][Full Text] [Related]
15. [Clinicopathologic features of cystic hypersecretory lesion of the breast].
Bi R; Cheng Y; Yu B; Shui R; Yang W; Xu X
Zhonghua Bing Li Xue Za Zhi; 2014 Jan; 43(1):25-9. PubMed ID: 24713245
[TBL] [Abstract][Full Text] [Related]
16. Intracystic papillary carcinomas of the breast: a reevaluation using a panel of myoepithelial cell markers.
Collins LC; Carlo VP; Hwang H; Barry TS; Gown AM; Schnitt SJ
Am J Surg Pathol; 2006 Aug; 30(8):1002-7. PubMed ID: 16861972
[TBL] [Abstract][Full Text] [Related]
17. Comparison of immunohistochemical staining in breast papillary neoplasms of cytokeratin 5/6 and p63 in core needle biopsies and surgical excisions.
Koo JS; Kim MJ; Kim EK; Park BW
Appl Immunohistochem Mol Morphol; 2012 Mar; 20(2):108-15. PubMed ID: 22553810
[TBL] [Abstract][Full Text] [Related]
18. Use of p63 and CD10 in the differential diagnosis of papillary neoplasms of the breast.
de Moraes Schenka NG; Schenka AA; de Souza Queiroz L; de Almeida Matsura M; Vassallo J; Alvarenga M
Breast J; 2008; 14(1):68-75. PubMed ID: 18086274
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic evaluation of papillary lesions of the breast on core biopsy.
Pathmanathan N; Albertini AF; Provan PJ; Milliken JS; Salisbury EL; Bilous AM; Byth K; Balleine RL
Mod Pathol; 2010 Jul; 23(7):1021-8. PubMed ID: 20473278
[TBL] [Abstract][Full Text] [Related]
20. Pathology of breast papillary neoplasms: Community hospital experience.
Vdovenko AA
Ann Diagn Pathol; 2020 Dec; 49():151605. PubMed ID: 32920473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]